Christian Macedonia in Singularity Hub:
Most work using AI in drug development intends to reduce the time and money it takes to bring one drug to market—currently 10 to 15 years and $1 billion to $2 billion. But can AI truly revolutionize drug development and improve success rates?
…Between 2010 and 2022, 20 AI-focused startups discovered 158 drug candidates, 15 of which advanced to clinical trials. Some of these drug candidates were able to complete preclinical testing in the lab and enter human trials in just 30 months, compared with the typical 3 to 6 years. This accomplishment demonstrates AI’s potential to accelerate drug development. On the other hand, while AI platforms may rapidly identify compounds that work on cells in a petri dish or in animal models, the success of these candidates in clinical trials—where the majority of drug failures occur—remains highly uncertain.
More here.
Enjoying the content on 3QD? Help keep us going by donating now.